Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Non Operating Income (2018 - 2025)

10x Genomics' Non Operating Income history spans 8 years, with the latest figure at $12.3 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 503.48% year-over-year to $12.3 million; the TTM value through Dec 2025 reached $21.1 million, up 1119.74%, while the annual FY2025 figure was $21.1 million, 1119.74% up from the prior year.
  • Non Operating Income for Q4 2025 was $12.3 million at 10x Genomics, up from $4.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $12.3 million in Q4 2025 and bottomed at -$3.0 million in Q4 2024.
  • The 5-year median for Non Operating Income is $1000.0 (2022), against an average of $1.6 million.
  • The largest YoY upside for Non Operating Income was 5592.68% in 2023 against a maximum downside of 3100.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$504000.0 in 2021, then surged by 1426.39% to $6.7 million in 2022, then crashed by 40.43% to $4.0 million in 2023, then tumbled by 176.57% to -$3.0 million in 2024, then soared by 503.48% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Non Operating Income are $12.3 million (Q4 2025), $4.0 million (Q3 2025), and -$1.1 million (Q2 2025).